Editorial: Role of the IL-23/IL-17 Pathway in Chronic Immune-Mediated Inflammatory Diseases: Mechanisms and Targeted Therapies

Elisabetta Bianchi (1) , Matteo Vecellio (2, 3) , Lars Rogge (1)

1 Immunorégulation - Immunoregulation
2 University of Oxford
3 IRCCS - Istituti di Ricovero e Cura a Carattere Scientifico

Editorial on the Research Topic Role of the IL-23/IL-17 Pathway in Chronic Immune-Mediated Inflammatory Diseases: Mechanisms and Targeted Therapies Chronic inflammatory diseases (CID) are clinically heterogeneous conditions that share common inflammatory pathways and derive from aberrant immune responses. The implication of the interleukin-23/interleukin-17 (IL-23/IL-17) axis in several CID is supported by studies in animal models of autoimmune disease (1, 2) and by the genome-wide association studies (GWAS) finding that several of the non-MHC loci genetically linked to Crohn’s disease, psoriasis, and axial spondyloarthritis (axSpA), are associated with genes in this pathway (IL23R, IL12B, IL6R, IL1R2, RORC, RUNX3, TYK2, JAK2, CARD9) (3–5).

Mots clés: chronic inflammatory diseases; spondyloarthritis; interleukin-23; interleukin-17; psoriasis

Domaines: Sciences du Vivant [q-bio]; Immunologie

Elisabetta Bianchi, Matteo Vecellio, Lars Rogge. Editorial: Role of the IL-23/IL-17 Pathway in Chronic Immune-Mediated Inflammatory Diseases: Mechanisms and Targeted Therapies. Frontiers in Immunology, 2021, 12, pp.770275. ⟨10.3389/fimmu.2021.770275⟩. ⟨pasteur-03497758⟩